The BioQuarter presentation from this years Academic Innovators session at Bio Spring Europe

1. Dr Diane Harbison
Edinburgh BioQuarter
Academic Innovators
BIO-Europe Spring 2014

2. EDINBURGH BIOQUARTER
Medical School
250 Researchers
Scottish Centre
for Regenerative
Medicine
230 Researchers
No 9, Bio Incubator
Royal
Infirmary
870 beds
Clinical Research
Imaging Centre
Queen’s Medical
Research Centre
650 Researchers
Clinical Research Facility
MHRA Accredited Phase 1 Unit
Anne Rowling
Regenerative
Neurology
Clinic

3. To establish Edinburgh BioQuarter as one of Europe’s leading
centres for Translational Medicine
OBJECTIVE
All located on one campus
• Clinicians • Scientists
• Patients • R&D Facilities
• Industry • Clinical Trial Facilities
• Academic Teaching Hospital • Commercialisation Expertise

4. SCIENTIFIC EXCELLENCE
Neuroscience
Infectious Diseases
Gastrointestinal
Inflammation/Immunology
Reproductive
Biology
Cardiovascular, Diabetes &
Endocrinology
Oncology
Regenerative Medicine
Renal Diseases
Rare and Orphan
Diseases
Respiratory

5. SCIENTIFIC EXCELLENCE
Neuroscience
Infectious Diseases
Gastrointestinal
Inflammation/Immunology
Reproductive
Biology
Cardiovascular, Diabetes &
Endocrinology
Oncology
Regenerative Medicine
Renal Diseases
Rare and Orphan
Diseases
Respiratory

6. Acute Pancreatitis
Identification of a key contributor
pathway mediating the many
inflammatory mechanisms that play a
role in severe acute pancreatits.
Experimental models in cells and in
rats and mice with experimental acute
pancreatitis.
In a position to develop new
medicines to take to clinical
application in patients.
Fibrosis
Decoded the molecular
understanding of the role of a key
antifibrotic protein.
Experimental evidence in models of
fibrosis.
In a position to take a clinically
relevant target into compound
screens for clinical application and on
into the clinic.
TWO PROJECTS

7. EXCELLENT FIT WITH GSK
- Discovery Partnership w/ Academia
Focus on the medicine
Collaborative partnerships focussed on drug discovery
Starts at any point from initiation of early screening, finishes with the
medicine
Undertake the best science
Minimal infrastructure – undertake projects independent of location or
disease area
Full access to all GSK drug discovery and development capabilities
Share in the investment, share in the reward
Both sides contribute - looks for a complementary match of skills
where GSK can make a positive contribution to success
Milestone funding with royalties. If GSK stops then the academic is free
to continue and progress

8. 1st DPAc Project
Acute Pancreatitis Project:
Mr Damian Mole & Dr Scott Webster
• Druggable target validated in Edinburgh
• Assays and screening sequence
• Active compounds
• Access to animal models of disease
• Access to patients
Collaboration Established in October 2011
Research & Clinical Milestones, Royalties on sales
3rd research event milestone achieved

9. 2nd DPAc Project
Fibrosis Project:
Dr Jonathan Fallowfield & Dr Scott Webster
• Druggable target, validated in Edinburgh
• Deep knowledge of targets & pathways
• Clinical Studies using natural ligand
• Access to Animal Models of disease
• Access to Patients
Agreement concluded February 2014
Research & Clinical Milestones, Royalties on sales

10. Neuroscience
Infectious Diseases
Gastrointestinal
Inflammation/Immunology
Reproductive
Biology
Cardiovascular, Diabetes &
Endocrinology
Oncology
Regenerative Medicine
Renal Diseases
Rare and Orphan
Diseases
Respiratory
OTHER COLLABORATIONS

11. THE BIOQUARTER
COMMERCIALISATION TEAM
Company Creation
Industrial Collaboration
Encouraging Entrepreneurship